{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:24:29Z","timestamp":1789658669216,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CPRIT","award":["RR200090"],"award-info":[{"award-number":["RR200090"]}],"id":[{"id":"https:\/\/ror.org\/0003xa228","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10549-026-08074-5","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:38:05Z","timestamp":1789533485000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study"],"prefix":"10.1007","volume":"219","author":[{"given":"Brian","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethania","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"McArthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"LeVee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Kordic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"J. Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"8074_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.JAA.0000580524.95733.3d","volume":"32","author":"EJ Watkins","year":"2019","unstructured":"Watkins EJ (2019) Overview of breast cancer. JAAPA Off J Am Acad Physician Assist 32:13\u201317. https:\/\/doi.org\/10.1097\/01.JAA.0000580524.95733.3d","journal-title":"JAAPA Off J Am Acad Physician Assist"},{"key":"8074_CR2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","volume":"57","author":"K-A Won","year":"2020","unstructured":"Won K-A, Spruck C (2020) Triple-negative breast cancer therapy: Current and future perspectives (Review). Int J Oncol 57:1245\u20131261. https:\/\/doi.org\/10.3892\/ijo.2020.5135","journal-title":"Int J Oncol"},{"key":"8074_CR3","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J et al (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med Mass Med Soc 382:810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med Mass Med Soc"},{"key":"8074_CR4","unstructured":"National Comprehensive Cancer Network (2026) NCCN guidelines version 3.2026 breast cancer [Internet]. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"key":"8074_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet Lond Engl 384:164\u2013172. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8","journal-title":"Lancet Lond Engl"},{"key":"8074_CR6","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I et al (2017) Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med Mass Med Soc 376:2147\u20132159. https:\/\/doi.org\/10.1056\/NEJMoa1612645","journal-title":"N Engl J Med Mass Med Soc"},{"key":"8074_CR7","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P et al (2021) Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med Mass Med Soc 384:2394\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa2105215","journal-title":"N Engl J Med Mass Med Soc"},{"key":"8074_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O\u2019Dea A et al (2024) Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol 10:227\u2013235. https:\/\/doi.org\/10.1001\/jamaoncol.2023.5033","journal-title":"JAMA Oncol"},{"key":"8074_CR9","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1078-0432.CCR-20-3646","volume":"27","author":"P Sharma","year":"2021","unstructured":"Sharma P, Kimler BF, O\u2019Dea A, Nye L, Wang YY, Yoder R et al (2021) Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I\u2013III Triple-negative Breast Cancer (NeoSTOP). Clin Cancer Res 27:975\u2013982. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3646","journal-title":"Clin Cancer Res"},{"key":"8074_CR10","doi-asserted-by":"publisher","first-page":"TPS629","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS629","volume":"42","author":"SR Stecklein","year":"2024","unstructured":"Stecklein SR, Aripoli A, Salgado R, O\u2019Dea A, Nye LE, Larson KE et al (2024) NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC). J Clin Oncol Wolters Kluwer 42:TPS629\u2013TPS629. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS629","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"8074_CR11","unstructured":"Clinical outcomes of patients with Stage I triple-negative breast cancer (TNBC) treated with or without chemotherapy: the mayo clinic experience - ASCO [Internet]. [cited 2026 May 15]. https:\/\/www.asco.org\/abstracts-presentations\/244547"},{"key":"8074_CR12","doi-asserted-by":"publisher","first-page":"103877","DOI":"10.1016\/j.breast.2025.103877","volume":"79","author":"Y-Z Zheng","year":"2025","unstructured":"Zheng Y-Z, Ying J-Q, Wu T-T, Su Y-H, Wang O-C (2025) Comparative survival outcomes of neoadjuvant and adjuvant therapy in patients with T1c, node-negative, triple-negative breast cancer: A population-based analysis. Breast Off J Eur Soc Mastology 79:103877. https:\/\/doi.org\/10.1016\/j.breast.2025.103877","journal-title":"Breast Off J Eur Soc Mastology"},{"key":"8074_CR13","doi-asserted-by":"publisher","first-page":"S311","DOI":"10.1016\/j.annonc.2024.08.179","volume":"35","author":"M de Graaf","year":"2024","unstructured":"de Graaf M, Gielen R, Balduzzi S, Siesling S, Linn S, Kok M (2024) 236MO Pathologic complete response and survival after neoadjuvant chemotherapy in Stage I TNBC: A registry-based study. Ann Oncol Elsevier 35:S311. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.179","journal-title":"Ann Oncol Elsevier"},{"key":"8074_CR14","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1200\/JCO.2013.53.1608","volume":"32","author":"I Vaz-Luis","year":"2014","unstructured":"Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB et al (2014) Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol Off J Am Soc Clin Oncol 32:2142\u20132150. https:\/\/doi.org\/10.1200\/JCO.2013.53.1608","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"8074_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/ITT.S126227","volume":"6","author":"JM Yoest","year":"2017","unstructured":"Yoest JM (2017) Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. ImmunoTargets Ther Dove Press 6:73\u201382. https:\/\/doi.org\/10.2147\/ITT.S126227","journal-title":"ImmunoTargets Ther Dove Press"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08074-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08074-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08074-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:38:16Z","timestamp":1789533496000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-08074-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8074"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08074-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"15 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective observational study involving human participants was conducted in accordance with the ethical standards of the 1964 Helsinki Declaration and was approved by the UT Southwestern Institutional Review Board (IRB number: STU-2023-0308). All medical data were presented in aggregate; no personally identifiable information was included in the manuscript.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. Gruber reports non-financial support from Hummingbird Bioscience and employment and stock ownership (immediate family member) from Guardant Health outside the submitted work. No other authors report competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"15"}}